Details for New Drug Application (NDA): 021732
✉ Email this page to a colleague
The generic ingredient in VANTAS is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.
Summary for 021732
Tradename: | VANTAS |
Applicant: | Endo Pharm |
Ingredient: | histrelin acetate |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | IMPLANT;SUBCUTANEOUS | Strength | 50MG | ||||
Approval Date: | Oct 12, 2004 | TE: | RLD: | Yes |
Expired US Patents for NDA 021732
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Endo Pharm | VANTAS | histrelin acetate | IMPLANT;SUBCUTANEOUS | 021732-001 | Oct 12, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Endo Pharm | VANTAS | histrelin acetate | IMPLANT;SUBCUTANEOUS | 021732-001 | Oct 12, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription